Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALT NASDAQ:PROK OTCMKTS:VXRT NASDAQ:ZSQR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALTAltimmune$3.08-2.5%$2.88$2.56▼$6.44$614.54M0.254.46 million shs4.34 million shsPROKProKidney$1.99-2.0%$1.80$0.59▼$7.13$613.18M1.611.33 million shs1.15 million shsVXRTVaxart$0.62-3.6%$0.63$0.26▼$0.84$155.41M1.09292,302 shs141,548 shsZSQRCoeptis Therapeutics$10.99$11.91$7.47▼$21.41$565.23M-0.25731,989 shs499,503 shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALTAltimmune-2.53%+4.76%+13.65%-8.88%-35.29%PROKProKidney-1.97%+5.29%+10.56%+8.74%+188.82%VXRTVaxart-3.59%+7.87%-0.48%-0.48%+42.82%ZSQRCoeptis Therapeutics0.00%-5.83%+8.60%+5.07%+44.23%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALTAltimmune$3.08-2.5%$2.88$2.56▼$6.44$614.54M0.254.46 million shs4.34 million shsPROKProKidney$1.99-2.0%$1.80$0.59▼$7.13$613.18M1.611.33 million shs1.15 million shsVXRTVaxart$0.62-3.6%$0.63$0.26▼$0.84$155.41M1.09292,302 shs141,548 shsZSQRCoeptis Therapeutics$10.99$11.91$7.47▼$21.41$565.23M-0.25731,989 shs499,503 shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALTAltimmune-2.53%+4.76%+13.65%-8.88%-35.29%PROKProKidney-1.97%+5.29%+10.56%+8.74%+188.82%VXRTVaxart-3.59%+7.87%-0.48%-0.48%+42.82%ZSQRCoeptis Therapeutics0.00%-5.83%+8.60%+5.07%+44.23%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALTAltimmune 2.55Moderate Buy$15.71410.20% UpsidePROKProKidney 2.71Moderate Buy$9.00352.26% UpsideVXRTVaxart 0.00N/AN/AN/AZSQRCoeptis Therapeutics 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest VXRT, ALT, PROK, and ZSQR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/25/2026PROKProKidney Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)6/24/2026ALTAltimmune Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)6/22/2026ALTAltimmune Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$10.006/2/2026ALTAltimmune CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform5/18/2026ALTAltimmune HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$25.00 ➝ $20.005/18/2026PROKProKidney HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$12.005/14/2026ALTAltimmune Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetMarket Outperform$14.00 ➝ $11.004/21/2026PROKProKidney Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 7/7/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALTAltimmune$40K14,974.19N/AN/A$1.99 per share1.55PROKProKidney$890K675.39N/AN/A($3.36) per share-0.59VXRTVaxart$237.26M0.63$0.10 per share6.25$0.37 per share1.67ZSQRCoeptis Therapeutics$1.36M415.60N/AN/A$2.63 per share4.18Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALTAltimmune-$88.09M-$0.93N/AN/AN/A-214,860.98%-42.57%-35.57%8/11/2026 (Estimated)PROKProKidney-$68.99M-$0.53N/AN/AN/A-8,131.50%N/A-21.39%8/11/2026 (Estimated)VXRTVaxart$16.33M$0.154.11N/AN/A14.51%61.43%20.07%N/AZSQRCoeptis Therapeutics-$11.92M-$2.52N/AN/AN/A-810.04%-92.29%-73.52%N/ALatest VXRT, ALT, PROK, and ZSQR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q1 2026PROKProKidney-$0.13-$0.14-$0.01-$0.14$0.10 million$0.23 million5/14/2026Q1 2026ZSQRCoeptis TherapeuticsN/A-$0.65N/A-$0.65N/A$0.11 million5/13/2026Q1 2026ALTAltimmune-$0.25-$0.18+$0.07-$0.18$0.00 millionN/A5/7/2026Q1 2026VXRTVaxart$0.02$0.02N/A$0.02$50.50 million$39.23 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthALTAltimmuneN/AN/AN/AN/AN/APROKProKidneyN/AN/AN/AN/AN/AVXRTVaxartN/AN/AN/AN/AN/AZSQRCoeptis TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALTAltimmune0.1229.5629.56PROKProKidneyN/A9.069.06VXRTVaxartN/A1.711.71ZSQRCoeptis Therapeutics0.013.253.25Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALTAltimmune78.05%PROKProKidney51.59%VXRTVaxart18.05%ZSQRCoeptis Therapeutics13.88%Insider OwnershipCompanyInsider OwnershipALTAltimmune1.60%PROKProKidney39.83%VXRTVaxart2.80%ZSQRCoeptis Therapeutics24.25%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALTAltimmune50194.47 million191.36 millionOptionablePROKProKidney3302.06 million181.75 millionOptionableVXRTVaxart120242.84 million236.04 millionNo DataZSQRCoeptis Therapeutics251.43 million38.96 millionNot OptionableVXRT, ALT, PROK, and ZSQR HeadlinesRecent News About These CompaniesCoeptis Therapeutics Holdings, Inc. (NASDAQ:ZSQR) Short Interest UpdateJuly 2, 2026 | americanbankingnews.comZ Squared Inc. Appoints Jeffrey Harris as Chief Technology OfficerJune 30, 2026 | prnewswire.comZ Squared Raises Approximately $15.3 Million in Non-Debt Capital to Advance AI Infrastructure StrategyJune 29, 2026 | prnewswire.comRussell Indexes Add Z Squared Inc. to Russell 2000® and Russell 3000®June 29, 2026 | prnewswire.comZ Squared, Inc. to Acquire Majority Interest in Paradox Data and Its Union County Campus, a Next-Generation Data Center Development Targeting Up to 150 MW of Firm PowerJune 25, 2026 | prnewswire.comZ Squared to Participate in Maxim Group's AI Data Center SummitJune 9, 2026 | prnewswire.comZ Squared, Inc. Enters $50 Million Committed Equity Forward Purchase Agreement to Support AI Infrastructure BuildoutJune 4, 2026 | prnewswire.comZ Squared, Inc. Announces Preliminary Inclusion in Russell 3000® and Russell 2000® IndexesMay 27, 2026 | prnewswire.comVanderbilt Report: Z Squared Locks In Zero-Cash, Zero-Debt Path to 42 MW of AI-Ready PowerMay 26, 2026 | globenewswire.comZ Squared, Inc. Outlines Phase 1 Plan to Reach 100 MW of AI-Ready Infrastructure for Inference WorkloadsMay 19, 2026 | prnewswire.comZ Squared Appoints Jon Najarian, Pete Najarian, Marc LoPresti and Jay Zapata to Newly Formed Advisory BoardMay 4, 2026 | prnewswire.comZ Squared to Acquire Skycore Digital, Adding 24 MW of Energized AI Infrastructure with Expansion Path to 42 MWApril 29, 2026 | prnewswire.comZ Squared, Inc. to Ring the Nasdaq Closing Bell in Celebration of Its Listing on the Nasdaq Global MarketApril 28, 2026 | prnewswire.comCoeptis Therapeutics Announces Approval of Z Squared Inc.'s Nasdaq Listing ApplicationApril 27, 2026 | finanznachrichten.deZ Squared Provides Additional Information on Previously Disclosed Pro Rata DistributionApril 27, 2026 | tmcnet.comCoeptis Therapeutics Receives Shareholder Approval Towards Z Squared MergerApril 27, 2026 | finanznachrichten.deZ Squared Inc.: Z Squared Announces Completion of Business Combination with Coeptis Therapeutics and Listing on the Nasdaq Global MarketApril 25, 2026 | finanznachrichten.deZ Squared Announces Completion of Business Combination with Coeptis Therapeutics and Listing on the Nasdaq Global MarketApril 24, 2026 | prnewswire.comCoeptis Therapeutics: Coeptis Announces Approval of Z Squared Inc.'s Nasdaq Listing ApplicationApril 9, 2026 | finanznachrichten.deWhy Coeptis Therapeutics Holdings, Inc.’s (COEP) Stock Is Up 10.60%April 9, 2026 | aaii.comANew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesWhat to Expect From Q2 Earnings as Tech Strength BroadensBy Thomas Hughes | June 14, 20263 Stocks With Fresh Catalysts to Watch Before July 4By Chris Markoch | June 8, 2026SpaceX Valuation Loses Altitude as AI Risks MountBy Jeffrey Neal Johnson | June 23, 2026Flying Under the Radar: Lockheed Martin's $2.8B Stealth SetupBy Jeffrey Neal Johnson | June 17, 2026Beyond the AI Trade: 3 Defensive Stocks Built for StabilityBy Thomas Hughes | June 20, 2026VXRT, ALT, PROK, and ZSQR Company DescriptionsAltimmune NASDAQ:ALT$3.08 -0.08 (-2.53%) Closing price 07/6/2026 04:00 PM EasternExtended Trading$3.13 +0.05 (+1.75%) As of 07:19 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.ProKidney NASDAQ:PROK$1.99 -0.04 (-1.97%) Closing price 07/6/2026 04:00 PM EasternExtended Trading$2.05 +0.06 (+3.02%) As of 07:24 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.Vaxart OTCMKTS:VXRT$0.62 -0.02 (-3.59%) As of 07/6/2026 03:59 PM EasternVaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.Coeptis Therapeutics NASDAQ:ZSQR$10.99 0.00 (0.00%) As of 07/6/2026 04:00 PM EasternCoeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy. The company also offers its drugs for acute myeloid leukemia and acute respiratory diseases. Coeptis Therapeutics Holdings, Inc. has co-development agreement Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. The company was founded in 2017 and is headquartered in Wexford, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Flash Crash or Cash? The AI Hardware Reset Investors Can’t Ignore KBR Insiders Are Buying While the Market Misreads Its Spinoff Doug Casey Calls AI a Super Bubble, Bets on Energy, Gold Miners and Grains Contrarian Alert: 5 Downgraded Stocks That May Reward Long-Term Investors This Edge AI Stock Just Got a Huge Vote of Confidence From Wall Street AI Is Selling Off, But These 5 Stocks Could Benefit Next MarketBeat Week in Review – 06/29 - 07/03 Analysts Just Raised Price Targets On These 3 Semiconductor Equipment Stocks Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
